Frontier orbitals in chemical and biological activity: Quantitative relationships and mechanistic implications

Drug Metabolism Reviews

Volumn 31, Issue 3, 1999, Pages 755-816

  Lewis, David F V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALIPHATIC AMINE; ALIPHATIC KETONE; AMINO ACID; ANILINE DERIVATIVE; ANTHRACENE DERIVATIVE; AROMATIC AMINE; AROMATIC COMPOUND; BENZ[A]ANTHRACENE; BENZENE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLOFIBRATE; DICHLORVOS; DIELDRIN; DIETHYLSTILBESTROL; ETHINYLESTRADIOL; MALATHION; MELATONIN DERIVATIVE; NITROSAMINE; PHENACETIN; POLYCHLORINATED BIPHENYL; RESERPINE; STEROID; THEOPHYLLINE; TOLBUTAMIDE; TOLUENE; TRYPTAMINE; UNINDEXED DRUG;

ALKYLATION; ARTICLE; CHEMICAL REACTION; ENERGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM CHEMISTRY; RECEPTOR BINDING;

AMINES; AMINO ACIDS; ANILINE MUSTARD; ANIMALS; BENZ(A)ANTHRACENES; HUMANS; KETONES; MELATONIN; MODELS, CHEMICAL; STEROIDS; TOLUENE; TRYPTAMINES;

EID: 0032799440     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101943     Document Type: Article

References (92)

1. K. Fukui, Recognition of stereochemical paths by orbital interaction, Acc. Chem. Res., 4, 57-64 (1971).
2. G. Klopman, A semi-empirical treatment of molecular structures II. Molecular terms and application to diatomic molecules, J. Am. Chem. Soc., 86, 4550-4557 (1964).
3. G. Klopman, Chemical reactivity and the concept of charge- and frontier-controlled reactions, J. Am. Chem. Soc., 90, 223-234 (1968).
4. G. Klopman and R. F. Hudson, Polyelectronic perturbation treatment of chemical reactivity, Theoret. Chim. Acta, 8, 165-174 (1967); R. F. Hudson and G. Klopman, A general perturbation treatment of chemical reactivity, Tetrahedron Lett., 1103-1108 (1967).
5. G. Klopman and R. F. Hudson, Polyelectronic perturbation treatment of chemical reactivity, Theoret. Chim. Acta, 8, 165-174 (1967); R. F. Hudson and G. Klopman, A general perturbation treatment of chemical reactivity, Tetrahedron Lett., 1103-1108 (1967).
6. L. Salem, Intermolecular orbital theory of the interaction between conjugated systems. I. General theory, J. Am. Chem. Soc., 90, 543-552, and 553-566 (1968).
7. I. Fleming, Frontier Orbitals and Organic Chemical Reactions, John Wiley & Sons, New York, 1980.
8. L. B. Kier, Molecular Orbital Theory in Drug Research, Academic Press, New York, 1971.
9. L. B. Kier (ed.), Molecular Orbital Studies in Chemical Pharmacology, Springer-Verlag, New York, 1970.
10. Z. Simon, Quantum Biochemistry and Specific Interactions, Abacus, London, 1976.
11. D. F. V. Lewis, COMPACT and the importance of frontier orbitals in toxicity mediated by the cytochrome P450 mono-oxygenase system, Toxicol. Model., 1, 85-97 (1995).
12. T. Clark, Handbook of Computational Chemistry, John Wiley & Sons, New York, 1985.
13. D. M. Hirst, A Computational Approach to Chemistry, Blackwell, Oxford, 1990.
14. A. Warshel, Computer Modeling of Chemical Reactions in Enzymes and Solutions, John Wiley & Sons, New York, 1997.
15. D. F. V. Lewis, MINDO/3: A review of the literature, Chem. Rev., 86, 1111-1123 (1986).
16. D. F. V. Lewis, MO-QSARs: A review of molecular orbital-generated quantitative structure-activity relationships, Prog. Drug Metab., 12, 205-255 (1990).
17. H. Kubinyi, QSAR and 3D QSAR in drug design 1 and 2, Drug Discovery Today, 2, 457-567, and 538-546 (1997).
18. P. W. Atkins and R. S. Friedman, Molecular Quantum Mechanics, Oxford University Press, Oxford, 1997.
19. J. N. Murrell and A. J. Harget, Semi-empirical Self-consistent-field Molecular Orbital Theory of Molecules, John Wiley & Sons, New York, 1972.
20. M. J. S. Dewar, Development and status of MINDO/3 and MNDO, J. Mol. Struct., 700, 41-50 (1983).
21. M. J. S. Dewar and R. C. Dougherty, The PMO Theory of Organic Chemistry, Plenum, New York, 1975.
22. M. J. S. Dewar and D. M. Storch, Comparative tests of theoretical procedures for studying chemical reactions, J. Am. Chem. Soc., 107, 3898-3902 (1985).
23. J. A. Pople and D. L. Beveridge, Approximate Molecular Orbital Theory, McGraw-Hill, New York, 1970.
24. W. G. Richards, Quantum Pharmacology, Butterworths, London, 1983.
25. G. A. Segal, Semi-empirical Methods of Electronic Structure Calculation, Plenum, New York, 1977.
26. R. McWeeney, Coulon's Valence, Oxford University Press, Oxford, 1979.
27. J. A. Pople, D. P. Santry, and G. A. Segal, Approximate self-consistent molecular orbital theory. I. Invariant procedures, J. Chem. Phys., 465, 129-135 (1965).
28. R. C. Bingham, M. J. S. Dewar, and D. H. Lo, MINDO/3: An improved version of the MINDO semi-empirical SCF-MO method, J. Am. Chem. Soc., 97, 1285-1293 (1975).
29. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart, AM1: A new general purpose quantum mechanical molecular model, J. Am. Chem. Soc., 107, 3902-3909 (1985).
30. D. F. V. Lewis, The calculation of molar polarizabilities by the CNDO/2 method: Correlation with the hydrophobic parameter, log P, J. Computat. Chem., 10, 145-151 (1989).
31. D. F. V. Lewis, Molecular orbital calculations on solvents and other small molecules: Correlation between electronic and molecular properties, J. Computat. Chem., 8, 1084-1089 (1987).
32. J. G. Vinter, A. Davis, and M. R. Saunders, Strategic approaches to drug design. I. An integrated software framework for molecular modelling, J. Computer-Aided Mol. Design, 1, 31-51 (1987).
33. C. R. E. Jefcoate, J. L. Graylor, and R. L. Calabrese, Ligand interactions with cytochrome P450. I. Binding of primary amines, Biochemistry, 8, 3455-3463 (1969).
34. D. F. V. Lewis and B. G. Lake, Molecular modelling of human CYP2B isoforms and their interaction with substrates, inhibitors and redox components, Xenobiotica, 27, 443-487 (1997).
35. D. F. V. Lewis, C. Ioannides, and D. V. Parks, Molecular modelling of mammalian cytochromes P450 and evaluation of chemical toxicity and metabolism using COMPACT, in QSAR and Molecular Modelling: Computational Tools and Biological Applications (F. Sanz, J. Giraldo, and F. Manaut, eds.), Prous, Barcelona, 1996, pp. 595-600.
36. D. F. V. Lewis, Cytochromes P450: Structure, Function and Mechanisms, Taylor & Francis, London, 1996.
37. A. D. Ayrton, M. McFarlane, R. Walker, S. Neville, and C. Ioannides, The induction of P450 I proteins by aromatic amines may be related to their carcinogenic potential, Carcinogenesis, 11, 803-809 (1990).
38. A. D. Ayrton, M. McFarlane, R. Walker, S. Neville, M. M. Coombs, and C. Ionnides, Induction of the P4501 family of proteins by polycyclic aromatic hydrocarbons: Possible relationship to their carcinogenicity, Toxicology, 60, 173-186 (1990).
39. D. F. V. Lewis, Quantitative structure-activity relationships in substrates, inducers and inhibitors of cytochrome P4501 (CYP1), Drug Metab. Rev., 29, 589-650 (1997).
40. D. F. V. Lewis, C. Ioannides, D. V. Parke, and R. Walker, Quantitative structure-activity relationships in some cooked food mutagens, Food Addit. Contam., 12, 715-724 (1995).
41. C. Hansch, Structure-activity relationships of chemical mutagens and carcinogens, in QSAR in Environmental Toxicology - IV (J. L. M. Hermens and A. Opperhuizen, eds.), Elsevier, Amsterdam, 1991, pp. 17-29.
42. A. Poso, A. von Wright, and J. Gynther, An empirical and theoretical study on mechanisms of mutagenic activity of hydrazine compounds, Mutat. Res., 332, 63-71 (1995).
43. R. Benigni and A. M. Richard, QSARs of mutagens and carcinogens: Two case studies illustrating problems in the construction of models for noncon-generic chemicals, Mutat. Res., 371, 29-49 (1996).
44. D. F. V. Lewis and J. M. Pratt, The P450 catalytic cycle and oxygenation mechanism, Drug Metab. Rev., 30, 739-786 (1998).
45. e test to NCI/NTP-screened chemicals. II. Genotoxic carcinogens and non-genotoxic non-carcinogens, Carcinogenesis, 13, 1437-1445 (1992).
46. R. Benigni, C. Andreoli, and A. Giuliani, Structure-activity studies of chemical carcinogenesis: Use of an electrophilic reactivity parameter in a new QSAR model, Carcinogenesis, 10, 55-61 (1989).
47. R. A. Marcus and N. Sutin, Electron transfers in chemistry and biology, Biochim. Biophys. Acta, 811, 265-322 (1985).
48. K. D. Perring, Application of tritium nuclear magnetic resonance spectroscopy in kinetic and labelling studies, Ph.D. thesis, Department of Chemistry, University of Surrey, 1979.
49. D. F. V. Lewis, Cytochromes P450: Structure, Function and Mechanism, Taylor & Francis, London, 1996.
50. R. A. Y. Jones, Physical and Mechanistic Organic Chemistry, Cambridge University Press, Cambridge, 1979.
51. K. Schofield, Aromatic Nitration, Cambridge University Press, Cambridge, 1980.
52. D. F. V. Lewis and D. V. Parke, The genotoxicity of benzanthracenes: A quantitative structure-activity study, Mutat. Res., 328, 207-214 (1995).
53. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Structural requirements for substrates of cytochromes P450 and P448, Chem.-Biol. Interact., 64, 39-60 (1987).
54. D. Sugden, N. W. S. Chong, and D. F. V. Lewis, Structural requirements at the melatonin receptor, Br. J. Pharmacol., 114, 618-623 (1995).
55. D. F. V. Lewis, U. Kitchen, D. Sugden, J. English, and J. Arendt, Molecular modelling of G-protein coupled receptors: The interaction between specific ligands and their binding sites, in Trends in QSAR and Molecular Modelling (C. G. Wermuth, ed.), Elsevier, Amsterdam, 1993, pp. 489-494.
56. D. F. V. Lewis, T. J. B. Gray, and B. G. Lake, The use of structure-activity relationships, in Drug Metabolism from Molecules to Man (D. J. Benford, J. W. Bridges, and G. G. Gibson, eds.), Taylor & Francis, London, 1987, pp. 369-378.
57. D. F. V. Lewis, Molecular orbital calculations on tumour inhibitory phenyl aziridines, Xenobiotica, 19, 341-356 (1989).
58. D. F. V. Lewis, Molecular orbital calculations on tumour-inhibitory aniline mustards: QSARs, Xenobiotica, 19, 243-251 (1989).
59. D. F. V. Lewis, P. G. Brantom, C. Ioannides, R. Walker, and D. V. Parke, Nitrosamine carcinogenesis: Rodent assays, quantitative structure-activity relationships and human risk assessment, Drug Metab. Rev., 29, 1055-1078 (1997).
60. D. F. V. Lewis, P. P. Tamburini, and G. G. Gibson, The interaction of a homologous series of hydrocarbons with hepatic cytochrome P450. Molecular orbital-derived electronic and structural parameters influencing the haemoprotein spin state, Chem.-Biol. Interact., 58, 289-299 (1986).
61. D. F. V. Lewis, B. G. Lake, M. Dickins, P. J. Eddershaw, M. H. Tarbit, and P. S. Goldfarb, Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: Evaluation of CYP2B6 substrate binding affinity, Xenobiotica, 29, 361-393 (1999).
62. D. F. V. Lewis, C. Ioannides, and D. V. Parke, An improved and updated version of the COMPACT procedure for the evaluation of P450-mediated chemical activation, Drug Metab. Rev., 30, 709-737 (1998).
63. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Prediction of chemical carcinogenicity from molecular and electronic structures: A comparison of MINDO/3 and CNDO/2 molecular methods, Toxicol. Lett., 45, 1-13 (1989).
64. D. F. V. Lewis, C. Ioannides, and D. V. Parke, Molecular modelling of mammalian cytochromes P450 and evaluation of chemical toxicity and metabolism using COMPACT, in QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications (F. Sanz, J. Giraldo, and F. Manaut, eds.), Prous, Barcelona, 1996, pp. 595-600.
65. J. J. P. Stewart, MOPAC: A semi-empirical molecular orbital program, J. Computer-Aided Mol. Design, 4, 1-45 (1990).
66. J. J. P. Stewart, Semi-empirical molecular orbital methods, Rev. Computat. Chem., 1, 45-81 (1990).
67. T. Sugimura, K. Wakabayashi, M. Nagao, and H. Esumi, A new class of carcinogens: Heterocyclic amines in cooked food, in Food, Nutrition and Chemical Toxicity (D. V. Parke, C. Ioannides, and R. Walker, eds.), Smith-Gordon, London, 1993, pp. 259-276.
68. F. Oesch, H. Glatt, and D. Utesch, Metabolic perspectives on in vitro tests, Xenobiotica, 18, 35-44 (1988).
69. P. G. Wislocki, K. M. Fiorentini, P. P. Fu, S. K. Yang, and A. Y. H. Lu, Tumour-initiating ability of the twelve monomethylbenz[a]anthracenes, Carcinogenesis, 3, 215-217 (1982).
70. R. W. Hay, Bio-Inorganic Chemistry, John Wiley & Sons, New York, 1984.
71. D. F. V. Lewis, C. Ioannides, R. Schulte-Hermann, and D. V. Parke, Quantitative structure-activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and increase in liver weight associated with increased DNA synthesis, J. Steroid Biochem. Mol. Biol. (submitted).
72. R. A. Glennon and P. K. Gessner, Serotonin receptor binding affinities of tryptamine analogues, J. Med. Chem., 22, 428-432 (1979).
73. R. H. Davies and L. H. Smith, Partial agonism of cardiac β-adrenoceptor blocking agents and competitive conformer-receptor occupancy, Int. J. Quantum Chem., Quantum Biol. Symp., 7, 331-345 (1980).
74. A. Scriabine (ed.), Pharmacology of Antihypertensive Drugs, Raven Press, New York, 1980.
75. M. C. Michel, β-Adrenergic receptors, in Receptor Data for Biological Experiments (H. N. Doods and J. C. A. van Meel, eds.), Ellis Horwood, Chichester, 1991, pp. 19-22.
76. S. Safe, S. Bandiera, T. Sawyer, B. Zmudzka, G. Mason, M. Romkes, M. A. Denomme, J. Sparling, A. B. Okey, and T. Fujita, Effects of structure on binding to the 2,3,7,8-TCDD-receptor protein and AHH induction: Halogenated biphenyls, Environ. Health Perspect., 61, 21-33 (1985).
77. M. A. Denomme, K. Homonoko, T. Fujita, T. Sawyer, and S. Safe, Effects of substituents on the cytosolic receptor binding avidities and aryl hydrocarbon hydroxylase induction potencies of 7-substituted 2,3-dichlorodibenzo-p-dioxins, Mol. Pharmacol., 27, 656-661 (1985).
78. A. H. Khan and W. C. J. Ross, Tumour-growth inhibitory nitrophenyl aziridines and related compounds: Structure-activity relationship, Chem.-Biol. Interact., 1, 27-47 (1970).
79. A. H. Khan and W. C. J. Ross, Tumour-growth inhibitory nitrophenyl aziridines and related compounds: Structure-activity relationships, Chem.-Biol. Interact., 4, 11-22 (1972).
80. T. J. Bardos, Z. F. Chmielewicz, and P. Hebborn, Structure-activity relationships of alkylating agents in cancer chemotherapy, Ann. NY Acad. Sci., 163, 1006-1025 (1968).
81. T. J. Bardos, N. Datta-Gupta, P. Hebborn, and D. J. Tiggle, A study of comparative chemical and biological activities of alkylating agents, J. Med. Chem., 8, 167-174 (1969).
82. D. F. V. Lewis, Molecular orbital calculations on tumour-inhibitory phenyl aziridines: QSARs, Xenobiotica, 19, 341-356 (1989).
83. J. S. Wishnok, M. C. Archer, A. S. Edelman, and W. M. Rand, Nitrosamine carcinogenicity: A quantitative Hansch-Taft structure-activity relationship, Chem.-Biol. Interact., 20, 43-54 (1978).
84. J. Sangster, Octanol-water partition coefficients of simple organic compounds, J. Phys. Chem. Ref. Data, 18, 1111-1229 (1989).
85. T. Suzuki and Y. Kudo, Automatic log P estimation based on combined additive modelling methods, J. Computer-Aided Mol. Design, 4, 155-198 (1990).
86. R. E. White and M. McCarthy, Active site mechanics of liver microsomal cytochrome P450, Arch. Biochem. Biophys., 246, 19-32 (1986).
87. D. F. V. Lewis, C. Ioannides, and D. V. Parke, A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4) and also their hydroxylation rates, Biochem. Pharmacol., 50, 619-625 (1995).
88. C. Hansch and A. J. Leo, Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley & Sons, New York, 1979.
89. N. Eldirdiri, Uptake and metabolic effects of some halogenoalkanes, Ph.D. Thesis, University of Surrey, Guildford, U.K., 1992.
90. C. Calleja, J. M. Pascussi, J. C. Mani, P. Maurel, and M. J. Vilarem, The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor, Nature Med., 4, 92-96 (1998).
91. S. A. Kliewer, J. T. Moore, L. Wade, J. L. Staudinger, M. A. Watson, S. A. Jones, D. D. McKee, B. B. Oliver, T. M. Willson, R. H. Zetterstrom, T. Perlmann, and J. M. Lehmann, An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway, Cell, 92, 73-82 (1998).
92. D. F. V. Lewis and B. G. Lake, Molecular modelling of the rat peroxisome proliferator-activated receptor α (rPPARα) by homology with the human retinoic acid X receptor α (hRXRα) and investigation of peroxisome proliferator binding interactions: QSARs, Toxicol. In Vitro, 12, 619-632 (1998).